Izrael - hebrejščina - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - תרחיף להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of diabetes.

Izrael - hebrejščina - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - תרחיף להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of diabetes.

Izrael - hebrejščina - Ministry of Health

novo nordisk ltd., israel - insulin (human) - תרחיף להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - treatment of diabetes mellitus.

Izrael - hebrejščina - Ministry of Health

novo nordisk ltd., israel - insulin (human) - תרחיף להזרקה - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - treatment of diabetes mellitus.

Izrael - hebrejščina - Ministry of Health

novo nordisk ltd., israel - insulin aspart - תרחיף להזרקה - insulin aspart 100 u/ml - insulin aspart - insulin aspart - treatment of diabetes mellitus.

Izrael - hebrejščina - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as monohydrate phosphate - טבליה - sitagliptin as monohydrate phosphate 50 mg; metformin hydrochloride 500 mg - metformin - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

Izrael - hebrejščina - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as monohydrate phosphate - טבליה - sitagliptin as monohydrate phosphate 50 mg; metformin hydrochloride 850 mg - metformin - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

Izrael - hebrejščina - Ministry of Health

tzamal bio-pharma ltd - metformin hydrochloride; pioglitazone as hydrochloride - טבליות מצופות פילם - metformin hydrochloride 850 mg; pioglitazone as hydrochloride 15 mg - metformin - metformin - competact is indicated as second line treatment of type 2 diabetes mellitus adult patients,particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

Izrael - hebrejščina - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - sitagliptin as monohydrate phosphate - טבליות מצופות פילם - sitagliptin as monohydrate phosphate 25 mg - sitagliptin - sitagliptin - januvia is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus.important limitations of use:januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings.januvia has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januvia.

Izrael - hebrejščina - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - sitagliptin as monohydrate phosphate - טבליות מצופות פילם - sitagliptin as monohydrate phosphate 50 mg - sitagliptin - sitagliptin - januvia is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus.important limitations of use:januvia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings.januvia has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januvia.